254 related articles for article (PubMed ID: 30413718)
1. Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer.
Liu Y; Xu J; Choi HH; Han C; Fang Y; Li Y; Van der Jeught K; Xu H; Zhang L; Frieden M; Wang L; Eyvani H; Sun Y; Zhao G; Zhang Y; Liu S; Wan J; Huang C; Ji G; Lu X; He X; Zhang X
Nat Commun; 2018 Nov; 9(1):4718. PubMed ID: 30413718
[TBL] [Abstract][Full Text] [Related]
2. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling.
Choi HJ; Jin S; Cho H; Won HY; An HW; Jeong GY; Park YU; Kim HY; Park MK; Son T; Min KW; Jang KS; Oh YH; Lee JY; Kong G
EMBO Rep; 2019 Oct; 20(10):e48058. PubMed ID: 31468695
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
4. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
5. miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.
Kim Y; Kim H; Park D; Han M; Lee H; Lee YS; Choe J; Kim YM; Jeoung D
Oncotarget; 2016 Mar; 7(9):10297-321. PubMed ID: 26863629
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
Huynh FC; Jones FE
PLoS One; 2014; 9(12):e114419. PubMed ID: 25532106
[TBL] [Abstract][Full Text] [Related]
7. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells.
Sahlberg KK; Hongisto V; Edgren H; Mäkelä R; Hellström K; Due EU; Moen Vollan HK; Sahlberg N; Wolf M; Børresen-Dale AL; Perälä M; Kallioniemi O
Mol Oncol; 2013 Jun; 7(3):392-401. PubMed ID: 23253899
[TBL] [Abstract][Full Text] [Related]
8. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of LncRNA GAS5 causes trastuzumab resistance in breast cancer.
Li W; Zhai L; Wang H; Liu C; Zhang J; Chen W; Wei Q
Oncotarget; 2016 May; 7(19):27778-86. PubMed ID: 27034004
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
[TBL] [Abstract][Full Text] [Related]
12. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
13. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.
Scaltriti M; Eichhorn PJ; Cortés J; Prudkin L; Aura C; Jiménez J; Chandarlapaty S; Serra V; Prat A; Ibrahim YH; Guzmán M; Gili M; Rodríguez O; Rodríguez S; Pérez J; Green SR; Mai S; Rosen N; Hudis C; Baselga J
Proc Natl Acad Sci U S A; 2011 Mar; 108(9):3761-6. PubMed ID: 21321214
[TBL] [Abstract][Full Text] [Related]
14. Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies.
Vicario R; Peg V; Morancho B; Zacarias-Fluck M; Zhang J; Martínez-Barriocanal Á; Navarro Jiménez A; Aura C; Burgues O; Lluch A; Cortés J; Nuciforo P; Rubio IT; Marangoni E; Deeds J; Boehm M; Schlegel R; Tabernero J; Mosher R; Arribas J
PLoS One; 2015; 10(6):e0129876. PubMed ID: 26075403
[TBL] [Abstract][Full Text] [Related]
15. GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells.
Gardaneh M; Shojaei S; Kaviani A; Behnam B
Breast Cancer Res Treat; 2017 Apr; 162(2):231-241. PubMed ID: 28116540
[TBL] [Abstract][Full Text] [Related]
16. Coamplification of
Floros KV; Lochmann TL; Hu B; Monterrubio C; Hughes MT; Wells JD; Morales CB; Ghotra MS; Costa C; Souers AJ; Boikos SA; Leverson JD; Tan M; Serra V; Koblinski JE; Arribas J; Prat A; Paré L; Miller TW; Dozmorov MG; Harada H; Windle BE; Scaltriti M; Faber AC
Proc Natl Acad Sci U S A; 2018 Mar; 115(11):E2594-E2603. PubMed ID: 29476008
[No Abstract] [Full Text] [Related]
17. MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN.
Ye X; Bai W; Zhu H; Zhang X; Chen Y; Wang L; Yang A; Zhao J; Jia L
BMB Rep; 2014 May; 47(5):268-73. PubMed ID: 24286315
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
19. The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene.
Tormo E; Adam-Artigues A; Ballester S; Pineda B; Zazo S; González-Alonso P; Albanell J; Rovira A; Rojo F; Lluch A; Eroles P
Sci Rep; 2017 Jan; 7():41309. PubMed ID: 28120942
[TBL] [Abstract][Full Text] [Related]
20. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
